CORDIS
EU research results

CORDIS

English EN

THE SAFETY PHARMACOLOGY OF ARTEMISININS WHEN USED TO REVERSE PATHOPHYSIOLOGY OF MALARIA IN PREGNANCY

Project information

Grant agreement ID: 200805

Status

Closed project

  • Start date

    1 March 2008

  • End date

    31 August 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 2 597 331

  • EU contribution

    € 1 948 880

Coordinated by:

LIVERPOOL SCHOOL OF TROPICAL MEDICINE

United Kingdom

Objective

Artemisinin based antimalarial drug combinations are recommended for the treatment of P.falciparum malaria infections throughout all malarial endemic areas of the world and in all populations, including women of child bearing age. The studies planned in this collaborative project are central to assessing the potential hazard posed by these drugs to the developing human foetus and thereby making evidence based recommendations on the risk:benefit of these drugs. Although clinical experience to date indicates the artemisinins to be safe, the area of reproductive toxicology demands special consideration. Data from the Chinese literature and our own studies confirm that the artemisinins are embryotoxic and potentially teratogenic in animal species at drug doses within the human therapeutic range. Based on over ten years of investigating the pharmacology of these drugs we have developed a hypothesis which can explain these teratogenic effects. Our hypothesis is based on the generation of reactive oxygen species (ROS) from cleavage of the artemisinin peroxide bridge and consequent embryofoetal damage to key biological macromolecules. Our hypothesis draws on parallels with the metabolic activation and teratogenic effects of the other established teratogens such as phenytoin

Coordinator

LIVERPOOL SCHOOL OF TROPICAL MEDICINE

Address

Pembroke Place
L35qa Liverpool

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 733 480

Administrative Contact

Stephen Ward (Prof.)

Participants (5)

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 384 880

UNIVERSIDADE DO ALGARVE

Portugal

EU Contribution

€ 194 680

UNIVERSITEIT LEIDEN

Netherlands

EU Contribution

€ 402 880

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 186 880

WORLD HEALTH ORGANIZATION

Switzerland

EU Contribution

€ 46 080

Project information

Grant agreement ID: 200805

Status

Closed project

  • Start date

    1 March 2008

  • End date

    31 August 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 2 597 331

  • EU contribution

    € 1 948 880

Coordinated by:

LIVERPOOL SCHOOL OF TROPICAL MEDICINE

United Kingdom